Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKFJXP)

Drug Name

BDB001 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Toll-like receptor (TLR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
DPV-001	DMMC3XR	Non-small-cell lung cancer	2C25.Y	Phase 2	[3]
IMO-8400	DMDPNCJ	Rheumatoid arthritis	FA20	Phase 2	[4]
IMO-9200	DMEHWPC	Autoimmune disease	4A40-4A45	Phase 1	[5]
PMID30280939-Compound-WO2009082440	DMXRHCJ	N. A.	N. A.	Patented	[6]
PMID30280939-Compound-US20179642901	DMPVW2Q	Malaria	1F40-1F45	Patented	[6]
PMID30280939-Compound-WO2015150568	DMGCE3Z	N. A.	N. A.	Patented	[6]
PMID30280939-Compound-WO200606195	DMLVSEK	N. A.	N. A.	Patented	[6]
PMID30280939-Compound-WO2005070959	DM6VP5K	N. A.	N. A.	Patented	[6]
PMID30280939-Compound-WO2013148426	DMUKIEJ	Malaria	1F40-1F45	Patented	[6]
PMID30280939-Compound-WO2013148427	DM4Z2KY	N. A.	N. A.	Patented	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT04819373) BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	UbiVac's DRibble, autophagosome-enriched vaccines: Applications for cancer and infectious disease. UbiVac. 2013.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847.